Insiders have been trading these 5 stocks: ((TEAM)), ((CRWV)), ((DUK)), ((TNXP)) and ((DXCM)). Here is a breakdown of their recent trades and their value.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Atlassian has seen a flurry of activity from its top executives, with significant stock sales taking place. CAO Gene Liu sold 168 shares for a total of $27,992, while President Anutthara Bharadwaj offloaded 1,682 shares, netting $280,265. CTO Rajeev Rajan Bashyam made a substantial sale of 3,026 shares, amounting to $504,207. CRO Brian Duffy also participated, selling 1,945 shares for $324,085. Director Joseph Leo Binz rounded out the sales with 1,715 shares sold for $285,762. These transactions highlight a period of strategic divestment among Atlassian’s leadership.
CoreWeave has experienced massive stock sales, primarily driven by Magnetar Financial LLC, a significant shareholder. Magnetar Financial sold 915,382 shares, generating $91,675,507, followed by another sale of 549,682 shares worth $55,398,351. Additionally, Director Jack D. Cogen executed a major transaction, selling 4,000,000 shares for an impressive $371,850,558. These large-scale sales indicate a major shift in CoreWeave’s shareholder landscape.
Duke Energy’s stock activity has been marked by sales from its senior vice presidents. Bonnie T. Titone, SVP and Chief Admin Officer, sold 2,000 shares for $248,760. Meanwhile, Alexander J. Weintraub, SVP and Chief Customer Officer, sold 400 shares, bringing in $48,656. These transactions suggest a trend of stock liquidation among Duke Energy’s top executives.
Tonix Pharma saw a different kind of transaction, with Director Taylor Carolyn E. purchasing 418 shares for a total of $15,060. This purchase stands out amidst a sea of sales in the market, indicating a vote of confidence in Tonix Pharma’s future prospects by its director.
Dexcom’s interim CFO, Mark Foletta, engaged in a modest sale of 195 shares, which amounted to $15,900. This transaction, while smaller in scale compared to others, reflects ongoing financial activity within Dexcom’s executive team, possibly signaling strategic financial planning or personal portfolio adjustments.